S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Electric Vehicles Can Drive Alcoa Stock Higher
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Electric Vehicles Can Drive Alcoa Stock Higher
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Electric Vehicles Can Drive Alcoa Stock Higher
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Electric Vehicles Can Drive Alcoa Stock Higher
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Bangladesh seeks China help to repatriate Rohingya refugees
NASDAQ:ONCR

Oncorus - ONCR Stock Forecast, Price & News

$1.52
-0.06 (-3.80%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$1.50
$1.62
50-Day Range
$1.07
$1.78
52-Week Range
$0.98
$14.12
Volume
32,800 shs
Average Volume
159,965 shs
Market Capitalization
$39.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.75

Oncorus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
409.9% Upside
$7.75 Price Target
Short Interest
Healthy
2.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-1.00mentions of Oncorus in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$6,464 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.63) to ($2.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

164th out of 1,293 stocks

Pharmaceutical Preparations Industry

67th out of 619 stocks

ONCR stock logo

About Oncorus (NASDAQ:ONCR) Stock

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ONCR. Chardan Capital began coverage on Oncorus in a report on Wednesday, June 15th. They set a "buy" rating and a $5.00 price objective on the stock. Piper Sandler decreased their price objective on Oncorus from $40.00 to $12.00 and set an "overweight" rating on the stock in a report on Wednesday, May 18th.

Oncorus Price Performance

Shares of Oncorus stock traded down $0.06 during midday trading on Friday, hitting $1.52. 32,860 shares of the company were exchanged, compared to its average volume of 57,771. The firm has a market cap of $39.34 million, a P/E ratio of -0.53 and a beta of 2.92. Oncorus has a 52 week low of $0.98 and a 52 week high of $14.12. The firm has a 50 day simple moving average of $1.38 and a 200-day simple moving average of $1.73.

Oncorus (NASDAQ:ONCR - Get Rating) last posted its earnings results on Wednesday, May 4th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.09. Equities research analysts expect that Oncorus will post -2.63 earnings per share for the current year.

Receive ONCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter.

ONCR Stock News Headlines

See More Headlines
Receive ONCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter.

ONCR Company Calendar

Last Earnings
11/03/2021
Today
8/08/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCR
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.75
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+409.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-64,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.04 per share

Miscellaneous

Free Float
21,768,000
Market Cap
$39.34 million
Optionable
Not Optionable
Beta
2.93














ONCR Stock - Frequently Asked Questions

Should I buy or sell Oncorus stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncorus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Oncorus stock.
View analyst ratings for Oncorus
or view top-rated stocks.

What is Oncorus' stock price forecast for 2022?

3 analysts have issued 1-year price objectives for Oncorus' shares. Their ONCR stock forecasts range from $5.00 to $12.00. On average, they predict Oncorus' share price to reach $7.75 in the next year. This suggests a possible upside of 409.9% from the stock's current price.
View analysts' price targets for Oncorus
or view top-rated stocks among Wall Street analysts.

How has Oncorus' stock performed in 2022?

Oncorus' stock was trading at $5.27 at the beginning of the year. Since then, ONCR stock has decreased by 71.2% and is now trading at $1.52.
View the best growth stocks for 2022 here
.

When is Oncorus' next earnings date?

Oncorus is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our earnings forecast for Oncorus
.

How were Oncorus' earnings last quarter?

Oncorus, Inc. (NASDAQ:ONCR) released its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.01.

What other stocks do shareholders of Oncorus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncorus investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV), Atlas Air Worldwide (AAWW).

When did Oncorus IPO?

(ONCR) raised $87 million in an initial public offering on Friday, October 2nd 2020. The company issued 5,800,000 shares at $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler acted as the underwriters for the IPO.

What is Oncorus' stock symbol?

Oncorus trades on the NASDAQ under the ticker symbol "ONCR."

Who are Oncorus' major shareholders?

Oncorus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Private Advisor Group LLC (0.31%) and Sawtooth Solutions LLC (0.30%). Company insiders that own Oncorus stock include Christophe Queva, Ernest C Garcia II, Luke Evnin, Rick Wanstall, Stephen Harbin and Sunstates Fund LP Mpm.
View institutional ownership trends for Oncorus
.

How do I buy shares of Oncorus?

Shares of ONCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oncorus' stock price today?

One share of ONCR stock can currently be purchased for approximately $1.52.

How much money does Oncorus make?

Oncorus (NASDAQ:ONCR) has a market capitalization of $39.34 million. The company earns $-64,760,000.00 in net income (profit) each year or ($2.85) on an earnings per share basis.

How many employees does Oncorus have?

Oncorus employs 82 workers across the globe.

How can I contact Oncorus?

The official website for Oncorus is www.oncorus.com. The company can be reached via phone at 857-320-6400 or via email at ir@oncorus.com.

This page (NASDAQ:ONCR) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.